Site Editor
William J. Gradishar, MD, FACP, FASCO
William J. Gradishar, MD, FACP, FASCO
Posted: Tuesday, July 2, 2024
According to a press release from Shorla Oncology, the U.S. Food and Drug Administration (FDA) approved its liquid form of thiotepa (Tepylute), which is used to treat patients with breast, ovarian, and bladder cancers. Also known as SH-105, this agent is a ready-to-dilute formulation that reportedly provides consistent dosing accuracy. The drug, which comes in a powdered form, is first mixed with a solvent or diluting agent and is administered to patients via injection.
This formulation of thiotepa “removes the necessity to reconstitute, which can introduce additional risks of drug preparation errors,” according to Rayna Herman, Chief Commercial Officer at Shorla Oncology.
JNCCN Spotlights
